The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy: A Pilot Study.
CONCLUSION: Subjects with AATD on SD augmentation therapy still exhibit inflammation, protease activity and elastin degradation that can be further improved by normalizing AAT levels. Higher AAT dosing than currently recommended may lead to enhanced clinical benefits and should be explored further. Clinical trial registration available at www.clinicaltrials.gov, ID NCT01669421.
PMID: 30965011 [PubMed - as supplied by publisher]
Source: American Journal of Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Campos MA, Geraghty P, Holt G, Mendes E, Newby PR, Ma S, Luna-Diaz LV, Turino GM, Stockley RA Tags: Am J Respir Crit Care Med Source Type: research
More News: Alpha-1 Antitrypsin Deficiency | Clinical Trials | Emphysema | Men | Respiratory Medicine | Study